^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CMTM6 expression + PD-L1 expression

    i
    Other names: CMTM6, CKLF Like MARVEL Transmembrane Domain Containing 6, CKLF-Like MARVEL Transmembrane Domain-Containing Protein 6, Chemokine-Like Factor Superfamily Member 6, Chemokine-Like Factor Super Family 6, Chemokine-Like Factor Superfamily 6, CKLFSF6, CKLF-Like MARVEL Transmembrane Domain Containing 6, FLJ20396, PRO2219, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126; 54918
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    10ms
    Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma. (PubMed, Int J Clin Exp Pathol)
    In conclusion, the expression of CMTM6 and PD-L1 is elevated in cervical cancer tissue and closely related to poor prognosis. Therefore, CMTM6 and PD-L1 may be new molecular targets for the treatment of cervical cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)
    |
    PD-L1 expression • CMTM6 expression + PD-L1 expression
    11ms
    Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer. (PubMed, Medicine (Baltimore))
    Patients with high CMTM6 expression exhibited significantly increased levels of PD-L1 expression and higher levels of tumor-infiltrating immune cells compared to patients with low CMTM6 expression. GO and KEGG analyses suggested that CMTM6 may be involved in multiple immune regulatory pathways in CRC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)
    |
    PD-L1 expression • PD-L1 overexpression • CMTM6 expression + PD-L1 expression
    over2years
    Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer. (PubMed, Biomed Res Int)
    Both CMTM6 and PD-L1 are highly expressed in TNBC, and their expressions are positively related. In the future, the two gene might become targets for the treatment of TNBC, providing a basis of clinical treatment of TNBC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)
    |
    PD-L1 expression • PD-L1 overexpression • CMTM6 expression + PD-L1 expression
    over2years
    The predictive value and correlation of β-catenin, CMTM6, and PD-L1 expression in colorectal cancer. (PubMed, Neoplasma)
    Expression of CMTM6 and PD-L1 in CRC are positively associated with β-catenin and reliable biomarkers for the prediction of responding to chemotherapy. The expression of β-catenin/CMTM6/PD-L1 and MMR status may be valuable biomarkers for guiding different treatment strategies in CRC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CMTM6 (CKLF Like MARVEL Transmembrane Domain Containing 6)
    |
    PD-L1 expression • MSI-H/dMMR • CMTM6 expression + PD-L1 expression